The use of growth factors, CD34(+) cells and fibrin for the management of chronic venous ulcers.

Autor: Romano F; Department of General Medicine, ASP Catanzaro, Catanzaro, Italy., Paolino FM; Department of Health Science, University of Catanzaro, Catanzaro, Italy.; Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini University Hospital, Catanzaro, Italy., Rizzo BA; Department of Health Science, University of Catanzaro, Catanzaro, Italy.; Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini University Hospital, Catanzaro, Italy., Russo A; Unical, University of Calabria, Rende (CS), Italy., Southworth S; North Mississippi Sports Medicine & Orthopaedic Clinic, PLLC, Tupelo, MS, USA., Serra R; Interuniversity Center of Phlebolymphology (CIFL), University Magna Graecia of Catanzaro, Catanzaro, Italy.; Department of Medical and Surgical Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy., Gallelli L; Department of Health Science, University of Catanzaro, Catanzaro, Italy. gallelli@unicz.it.; Clinical Pharmacology and Pharmacovigilance Operative Unit, Mater Domini University Hospital, Catanzaro, Italy. gallelli@unicz.it.
Jazyk: angličtina
Zdroj: International wound journal [Int Wound J] 2016 Oct; Vol. 13 (5), pp. 1011-3. Date of Electronic Publication: 2015 Sep 15.
DOI: 10.1111/iwj.12500
Abstrakt: Chronic venous ulceration represents a very common event. Current standard treatment includes local wound care with the application of compression. We report the effects of platelet-rich plasma in patients with chronic venous ulcers, which is able to stimulate fibroblasts, macrophages and mesenchymal cells and growth factors in order to achieve re-epithelialisation and neovascularisation within the microenviroment of the wound. We also documented the efficacy of this method as the sole treatment without surgical procedures.
(© 2015 Medicalhelplines.com Inc and John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: